Resultados de la búsqueda

Peiró-Aventín B, Cabrera-Romero E, Mora-Ayestarán N, Domínguez F, González-López E, García-Pavía P. Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis. Rev Esp Cardiol (2024) 77:426-428.
Link to the full text in Repisalud

Fernández-Cisnal A, Avanzas P, Filgueiras-Rama D, Garcia-Pavia P, Sanchis L, Sanchis J. ChatGPT-4 versus human assessment in cardiology peer review. Rev Esp Cardiol (2024) S1885-5857:00066-5.

Restrepo-Córdoba MA, Chmielewski P, Truszkowska G, Peña-Peña ML, Kubánek M, Krebsová A, Lopes LR, García-Ropero Á, Merlo M, Paldino A, Peters S, Jurcut R, Barriales-Villa R, Zorio E, Hazebroek M, Mogensen J, García-Pavía P. Pregnancy in women with dilated cardiomyopathy genetic variants. Rev Esp Cardiol (2024) (24):00128-2.
Link to the full text in Repisalud

García-Pavía P, Manuel García-Pinilla J, Lozano-Bahamonde A, Yun S, García-Quintana A, Gavira-Gómez JJ, Aibar-Arregui MÁ, Barge-Caballero G, Villota JN, Bernal L, Tarilonte P. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol (2024) S1885-5857:00240-8.

Saturi G, De Frutos F, Sguazzotti M, Gonzalez-Lopez E, Nardi E, Domínguez F, Ponziani A, Cabrera E, Caponetti AG, Lozano S, Massa P, Cobo-Marcos M, Accietto A, Castro-Urda V, Giovannetti A, Toquero J, Gagliardi C, Gómez-Bueno M, Rios-Tamayo R, Biagini E, Segovia J, Galiè N, García-Pavía P, Longhi S. Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis. Heart (2024) 110:40-48

Yun S, Palladini G, Anderson LJ, Cariou E, Wang R, Angeli FS, Ebede B, Garcia-Pavia P. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction. Amyloid (2024) :1-11

de Frutos F, Saturi G, Gonzalez-Lopez E, Sguazzotti M, Dominguez F, Ponziani A, Cabrera-Romero E, Caponetti AG, Lozano S, Massa P, Peiro-Aventin B, Accietto A, Mora-Ayestarán N, Giovannetti A, Castro-Urda V, Gagliardi C, Cobo-Marcos M, Rios-Tamayo R, Biagini E, Gomez-Bueno M, Galiè N, Segovia-Cubero J, Longhi S, Garcia-Pavia P. Incidence and predictors of sudden death in patients with cardiac amyloidosis. Amyloid (2024) :1-5

Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA‐HCM Investigators. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc (2024) 13:e035993

Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS; REDWOOD-HCM Investigators. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail (2024) S1071-9164:00082-4
Link to the full text in Repisalud

Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Angeli FS, Maurer MS; THAOS investigators. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail (2024) S1071-9164:00222-7
Link to the full text in Repisalud